AVITA Medical Reports Quarter Ending December 31, 2021, and Transition Period July 1, 2021, to December 31, 2021, Financial Results
28. Februar 2022 16:01 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 28, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the “Company”), a regenerative medicine company that is developing and...
The RECELL® System Receives PMDA Approval in Japan and AVITA Medical will Commercialize in Partnership with COSMOTEC, an M3 Group Company
23. Februar 2022 16:29 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
AVITA Medical to Present at the Cowen 42nd Annual Health Care Conference
23. Februar 2022 16:01 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use
17. Februar 2022 16:01 ET
|
AVITA Medical
System enhanced in response to clinician workflow and usability feedback; new system simplifies process United States product launch planned for Q2 2022 VALENCIA, Calif. and MELBOURNE,...
AVITA Medical to Announce Transition Period July 1, 2021 to December 31, 2021 Financial Results
15. Februar 2022 16:01 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
AVITA Medical to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
02. Februar 2022 16:01 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 02, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
RECELL® System Data to be Presented at 44th Annual John A. Boswick Burn & Wound Care Symposium
24. Januar 2022 08:00 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Jan. 24, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
AVITA Medical Announces Preliminary Unaudited Results for the Quarter ended December 31, 2021
10. Januar 2022 08:00 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia., Jan. 10, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the “Company”), a regenerative medicine company that is developing and...
AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Soft-Tissue Reconstruction
06. Januar 2022 16:01 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...
AVITA Medical Establishes Proof of Concept for Novel Treatments Using Genetically-Modified Skin Cells
06. Januar 2022 08:00 ET
|
AVITA Medical
VALENCIA, Calif. and MELBOURNE, Australia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a...